Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

98.04 +1.01 (+1.04%)
Streaming Delayed Price Updated: 1:36 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
24 25 Next >
News headline image
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison ↗
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and... 
Via Benzinga
News headline image
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival ↗
Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer. 
Via Investor's Business Daily
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Analyst Ratings for Incyte ↗
 
Via Benzinga
News headline image
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share ↗
Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago. 
Via Benzinga
News headline image
Incyte's Earnings Outlook ↗
 
Via Benzinga
News headline image
Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales ↗
Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts. 
Via Investor's Business Daily
News headline image
Why Incyte Shares Are Falling Today ↗
Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the  
Via Benzinga
News headline image
Earnings Outlook For Incyte ↗
 
Via Benzinga
News headline image
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
News headline image
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
News headline image
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023 ↗
 
Via Benzinga
News headline image
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End ↗
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host... 
Via Benzinga
News headline image
'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Alexandria Real Estate Equities, Inc. (NYSE: ARE) is "one of the better real estate investment trusts, but I would rather see you in Federal... 
Via Benzinga
News headline image
Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children ↗
Incyte Corporation (NASDAQ: INCY) released topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with  
Via Benzinga
News headline image
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape ↗
Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a  
Via Benzinga
News headline image
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
News headline image
2 Low-Priced Stocks That Could Make You Richer ↗
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
News headline image
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
News headline image
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
From Incyte
Via Business Wire
News headline image
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review ↗
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗
 
Via Benzinga
News headline image
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
From Incyte
Via Business Wire
News headline image
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks ↗
Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2.  Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain... 
Via Benzinga
News headline image
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
From Incyte
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.